Anti-bacterial effects of enzymatically-isolated sialic acid from glycomacropeptide in a Helicobacter pylori-infected murine model
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: Helicobacter pylori (H. pylori) colonization of the stomach mucosa and duodenum is the major cause of acute and chronic gastroduodenal pathology in humans. Efforts to find effective anti-bacterial strategies against H. pylori for the non-antibiotic control of H. pylori infection are urgently required. In this study, we used whey to prepare glycomacropeptide (GMP), from which sialic acid (G-SA) was enzymatically isolated. We investigated the anti-bacterial effects of G-SA against H. pylori in vitro and in an H. pylori-infected murine model. MATERIALS/METHODS: The anti-bacterial activity of G-SA was measured in vitro using the macrodilution method, and interleukin-8 (IL-8) production was measured in H. pylori and AGS cell co-cultures by ELISA. For in vivo study, G-SA 5 g/kg body weight (bw)/day and H. pylori were administered to mice three times over one week. After one week, G-SA 5 g/kg bw/day alone was administered every day for one week. Tumor necrosis factor-α (TNF-α), IL-1β, IL-6, and IL-10 levels were measured by ELISA to determine the anti-inflammatory effects of G-SA. In addition, real-time PCR was performed to measure the genetic expression of cytotoxin-associated gene A (cagA). RESULTS: G-SA inhibited the growth of H. pylori and suppressed IL-8 production in H. pylori and in AGS cell co-cultures in vitro. In the in vivo assay, administration of G-SA reduced levels of IL-1β and IL-6 pro-inflammatory cytokines whereas IL-10 level increased. Also, G-SA suppressed the expression of cagA in the stomach of H. pylori-infected mice. CONCLUSION: G-SA possesses anti-H. pylori activity as well as an anti-H. pylori-induced gastric inflammatory effect in an experimental H. pylori-infected murine model. G-SA has potential as an alternative to antibiotics for the prevention of H. pylori infection and H. pylori-induced gastric disease prevention.
Abstract
BACKGROUND/OBJECTIVES: Helicobacter pylori (H. pylori) colonization of the stomach mucosa and duodenum is the major cause of acute and chronic gastroduodenal pathology in humans. Efforts to find effective anti-bacterial strategies against H. pylori for the non-antibiotic control of H. pylori infection are urgently required. In this study, we used whey to prepare glycomacropeptide (GMP), from which sialic acid (G-SA) was enzymatically isolated. We investigated the anti-bacterial effects of G-SA against H. pylori in vitro and in an H. pylori-infected murine model. MATERIALS/METHODS: The anti-bacterial activity of G-SA was measured in vitro using the macrodilution method, and interleukin-8 (IL-8) production was measured in H. pylori and AGS cell co-cultures by ELISA. For in vivo study, G-SA 5 g/kg body weight (bw)/day and H. pylori were administered to mice three times over one week. After one week, G-SA 5 g/kg bw/day alone was administered every day for one week. Tumor necrosis factor-α (TNF-α), IL-1β, IL-6, and IL-10 levels were measured by ELISA to determine the anti-inflammatory effects of G-SA. In addition, real-time PCR was performed to measure the genetic expression of cytotoxin-associated gene A (cagA). RESULTS: G-SA inhibited the growth of H. pylori and suppressed IL-8 production in H. pylori and in AGS cell co-cultures in vitro. In the in vivo assay, administration of G-SA reduced levels of IL-1β and IL-6 pro-inflammatory cytokines whereas IL-10 level increased. Also, G-SA suppressed the expression of cagA in the stomach of H. pylori-infected mice. CONCLUSION: G-SA possesses anti-H. pylori activity as well as an anti-H. pylori-induced gastric inflammatory effect in an experimental H. pylori-infected murine model. G-SA has potential as an alternative to antibiotics for the prevention of H. pylori infection and H. pylori-induced gastric disease prevention.
참고문헌 (29)
- Suerbaum S, "Helicobacter pylori infection", N Engl J Med, 347, pp.1175~1186 (2002)
- Venerito M, "Helicobacter pylori and gastrointestinal malignancies", Helicobacter, 20(Suppl 1), pp.36~39 (2015)
- Cover TL, "Helicobacter pylori infection, a paradigm for chronic mucosal inflammation: pathogenesis and implications for eradication and prevention", Adv Intern Med, 41, pp.85~117 (1996)
- Borén T, "Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens", Science, 262, pp.1892~1895 (1993)
- Kobayashi Y, "Adhesion of Helicobacter pylori to gastric epithelial cells in primary cultures obtained from stomachs of various animals", Infect Immun, 61, pp.4058~4063 (1993)
- Bodger K, "Helicobacter pylori and gastric inflammation", Br Med Bull, 54, pp.139~150 (1998)
- Huang J, "Stimulation of interleukin-8production in epithelial cell lines by Helicobacter pylori", Infect Immun, 63, pp.1732~1738 (1995)
- Harris PR, "Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and inflammatory cytokine production", Gastroenterology, 111, pp.419~425 (1996)
- Jones KR, "A tale of two toxins: Helicobacter pylori CagA and VacA modulate host pathways that impact disease", Front Microbiol, 1, pp.115~ (2010)
- Kaji T, "Adherence of Helicobacter pylori to gastric epithelial cells and mucosal inflammation", J Lab Clin Med, 139, pp.244~250 (2002)
- Varki NM, "Diversity in cell surface sialic acid presentations:implications for biology and disease", Lab Invest, 87, pp.851~857 (2007)
- Vimr ER, "Diversity of microbial sialic acid metabolism", Microbiol Mol Biol Rev, 68, pp.132~153 (2004)
- Carson CF, "Non-antibiotic therapies for infectious diseases", Commun Dis Intell Q Rep, 27(Suppl), pp.S143~S146 (2003)
- Kamiji MM, "Non-antibiotic therapies for Helicobacter pylori infection", Eur J Gastroenterol Hepatol, 17, pp.973~981 (2005)
- Yang JC, "Effective prevention and treatment of Helicobacter pylori infection using a combination of catechins and sialic acid in AGS cells and BALB", c mice, 2008, pp.138, 2084~2090
- Wang YC, "Medicinal plant activity on Helicobacter pylori related diseases", World J Gastroenterol, 20, pp.10368~10382 (2014)
- Ando T, "Interleukin-8 activity correlates with histological severity in Helicobacter pylori-associated antral gastritis", Am J Gastroenterol, 91, pp.1150~1156 (1996)
- Lee A, "A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain", Gastroenterology, 112, pp.1386~1397 (1997)
- Shimoyama T, "Bacterial factors and immune pathogenesis in Helicobacter pylori infection", Gut, 43(Suppl 1), pp.S2~S5 (1998)
- Simon PM, "Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides", Infect Immun, 65, pp.750~757 (1997)
- Kudo T, "Pattern of transcription factor activation in Helicobacter pylori-infected Mongolian gerbils", Gastroenterology, 132, pp.1024~1038 (2007)
- Yamamoto T, "Role of tumor necrosis factor-alpha and interferon-gamma in Helicobacter pylori infection", Microbiol Immunol, 48, pp.647~654 (2004)
- Thalmaier U, "Role of tumor necrosis factor alpha in Helicobacter pylori gastritis in tumor necrosis factor receptor 1-deficient mice", Infect Immun, 70, pp.3149~3155 (2002)
- Bodger K, "Gastric mucosal secretion of interleukin-10: relations to histopathology, Helicobacter pylori status, and tumour necrosis factor-alpha secretion", Gut, 40, pp.739~744 (1997)
- Bodger K, "Interleukin 10 in Helicobacter pylori associated gastritis: immunohistochemical localisation and in vitro effects on cytokine secretion", J Clin Pathol, 54, pp.285~292 (2001)
- Berg DJ, "Rapid development of severe hyperplastic gastritis with gastric epithelial dedifferentiation in Helicobacter felis-infected IL-10(-", -) mice, 1998, pp.152, 1377~1386
- Lindén SK, "Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches", Helicobacter, 13, pp.81~93 (2008)
- Nakayama J, "Experimental Glycoscience", pp.227~229 (2008), Springer
- Lee H, "α1,4GlcNAc-capped mucin-type O-glycan inhibits cholesterol α-glucosyltransferase from Helicobacter pylori and suppresses H. pylori growth", Glycobiology, 18, pp.549~558 (2008)